Friday, July 10, 2026

pharma · Diphtheria · Diabetes Mellitus, Type 2

Sanofi Pasteur MSD

Sanofi Pasteur MSD clinical programs — 42 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

France, LYON HQ
363 Employees
EMA registrant Type
Company details
Status
Public
HQ
France, LYON
Employees
363
Programs
83
Drugs
66
Patents
0
Intelligence · Clinical Programs

Sanofi Pasteur MSD projects

42 ClinicalTrials.gov programs sponsored by Sanofi Pasteur MSD.

Sanofi Pasteur MSD has 42 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Alirocumab

    Sanofi Pasteur

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule completed

    1 trial
  2. Alirocumab

    Sanofi Pasteur

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial
  3. CABAZITAXEL

    Sanofi Pasteur

    Prostate Cancer Metastatic

    phase 3 small molecule completed

    1 trial
  4. CYD Dengue Vaccine

    Sanofi Pasteur

    Dengue Fever

    phase 3 mab terminated

    1 trial
  5. CYD32

    Sanofi Pasteur

    Dengue Fever

    phase 3 mab completed

    1 trial
  6. ChimeriVax-JE, Japanese Encephalitis vaccine

    Sanofi Pasteur

    Encephalitis

    phase 3 mab completed

    1 trial
  7. DTaP-HB-PRP~T combined vaccine

    Sanofi Pasteur

    Diphtheria

    phase 3 mab completed

    1 trial
  8. DTaP-HB-PRP~T vaccine

    Sanofi Pasteur

    Diphtheria

    phase 3 mab completed

    1 trial
  9. Docetaxel

    Sanofi Pasteur

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial
  10. Doxorubicine + docetaxel sequential

    Sanofi Pasteur

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial
  11. Enoxaparin sodium (XRP4563)

    Sanofi Pasteur

    Myocardial Infarction

    phase 3 small molecule completed

    1 trial
  12. Hexaxim®

    Sanofi Pasteur

    Diphtheria

    phase 3 mab completed

    1 trial
  13. Insulin glargine/Lixisenatide (HOE901/AVE0010)

    Sanofi Pasteur

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial
  14. Isatuximab SAR650984

    Sanofi Pasteur

    Plasma Cell Myeloma

    phase 3 small molecule active

    1 trial
  15. Japanese encephalitis vaccine

    Sanofi Pasteur

    Japanese Encephalitis

    phase 3 mab completed

    1 trial
  16. Live attenuated Japanese encephalitis chimeric virus vaccine

    Sanofi Pasteur

    Japanese Encephalitis

    phase 3 mab completed

    1 trial
  17. Lixisenatide (AVE0010)

    Sanofi Pasteur

    Acute Coronary Syndrome

    phase 3 small molecule completed

    1 trial
  18. MEQ00073

    Sanofi Pasteur

    Meningococcal infection

    phase 3 small molecule active

    1 trial
  19. MEQ00074

    Sanofi Pasteur

    Meningococcal Infection

    phase 3 mab completed

    1 trial
  20. MEQ00089

    Sanofi Pasteur

    Healthy volunteers (Meningococcal infection)

    phase 3 small molecule active

    1 trial
  21. MET55

    Sanofi Pasteur

    Meningococcal Immunization

    phase 3 mab completed

    1 trial
  22. PCV21

    Sanofi Pasteur

    Pneumococcal Infections

    phase 3 mab active

    1 trial
  23. PCV21 vaccine

    Sanofi Pasteur

    Pneumococcal Immunization

    phase 3 mab active

    1 trial
  24. PVRV

    Sanofi Pasteur

    Rabies

    phase 3 mab completed

    1 trial
  25. Placebo

    Sanofi Pasteur

    Osteoarthritis

    phase 3 small molecule completed

    1 trial
  26. Placebo

    Sanofi Pasteur

    Colorectal Neoplasms

    phase 3 small molecule completed

    1 trial
  27. Rimonabant

    Sanofi Pasteur

    Obesity

    phase 3 small molecule terminated

    1 trial
  28. SR34006 (idraparinux sodium) Injection

    Sanofi Pasteur

    Pulmonary Embolism

    phase 3 small molecule completed

    1 trial
  29. Sarilumab

    Sanofi Pasteur

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial
  30. Semuloparin sodium

    Sanofi Pasteur

    Venous Thromboembolism

    phase 3 small molecule terminated

    1 trial
  31. Teplizumab

    Sanofi Pasteur

    Type 1 Diabetes Mellitus

    phase 3 small molecule active

    1 trial
  32. Tolebrutinib

    Sanofi Pasteur

    Non-relapsing Secondary Progressive Multiple Sclerosis

    phase 3 small molecule completed

    1 trial
  33. Vandetanib

    Sanofi Pasteur

    Non Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial
  34. Vandetanib

    Sanofi Pasteur

    Locally Advanced or Metastatic Medullary Thyroid Cancer

    phase 3 small molecule completed

    1 trial
  35. Venglustat GZ402671

    Sanofi Pasteur

    Congenital Cystic Kidney Disease

    phase 3 small molecule terminated

    1 trial
  36. ZD6474 (vandetanib)

    Sanofi Pasteur

    Non-Small-Cell Lung Carcinoma

    phase 3 small molecule completed

    1 trial
  37. afuzosin

    Sanofi Pasteur

    Benign Prostatic Hyperplasia

    phase 3 small molecule completed

    1 trial
  38. fexofenadine HCL (M016455)

    Sanofi Pasteur

    Rhinitis Seasonal

    phase 3 small molecule completed

    1 trial
  39. fitusiran

    Sanofi Pasteur

    Hemophilia A

    phase 3 small molecule completed

    1 trial
  40. hydroxychloroquine (Z0188)

    Sanofi Pasteur

    Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial
  41. lixisenatide AVE0010

    Sanofi Pasteur

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial
  42. placebo (saline)

    Sanofi Pasteur

    Sphingomyelin Lipidosis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Sanofi Pasteur MSD have?

42 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.